CG Oncology Inc

NASDAQ:CGONUnited States

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Contact Information

Headquarters

400 Spectrum Center Drive, Suite 2040IRVINE, CA, United States 92618

Phone

949-288-6298

Fax

302-531-3150

Executives

Chairman of the Board, Chief Executive Officer

Arthur Kuan

President, Chief Operating Officer

Ambaw Bellete

Chief Financial Officer

Stephen Dipalma

Chief Medical Officer

Vijay Kasturi

Lead Independent Director

Leonard Post